WO2016063289A3 - Compositions de comprimé pharmaceutique comprenant de la rifaximine - Google Patents
Compositions de comprimé pharmaceutique comprenant de la rifaximine Download PDFInfo
- Publication number
- WO2016063289A3 WO2016063289A3 PCT/IN2015/000312 IN2015000312W WO2016063289A3 WO 2016063289 A3 WO2016063289 A3 WO 2016063289A3 IN 2015000312 W IN2015000312 W IN 2015000312W WO 2016063289 A3 WO2016063289 A3 WO 2016063289A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rifaximin
- pharmaceutical tablet
- tablet compositions
- compositions
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne une composition de comprimé pharmaceutique comprenant de la rifaximine et un procédé de préparation de celle-ci.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3379MU2014 | 2014-10-22 | ||
| IN3379/MUM/2014 | 2014-10-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2016063289A2 WO2016063289A2 (fr) | 2016-04-28 |
| WO2016063289A3 true WO2016063289A3 (fr) | 2016-07-14 |
Family
ID=55761708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2015/000312 WO2016063289A2 (fr) | 2014-10-22 | 2015-08-04 | Compositions de comprimé pharmaceutique comprenant de la rifaximine |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2016063289A2 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1698630E (pt) | 2005-03-03 | 2014-09-15 | Alfa Wassermann Spa | Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais |
| CA2940601C (fr) | 2014-05-12 | 2021-08-24 | Alfa Wassermann S.P.A. | Nouvelle forme cristalline solvatee de la rifaximine, production, compositions et utilisations associees |
| RS63751B1 (sr) * | 2016-09-30 | 2022-12-30 | Salix Pharmaceuticals Inc | Čvrsti disperzioni oblici rifaksimina |
| EP3902528A1 (fr) * | 2018-12-19 | 2021-11-03 | Friulchem SpA | Procédé de fabrication d'un comprimé de rifaximine et comprimé de rifaximine |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090312357A1 (en) * | 2006-09-22 | 2009-12-17 | Cipla Limited | Rifaximin |
| US20120245192A1 (en) * | 2010-09-22 | 2012-09-27 | Alfa Wassermann, S.P.A. | Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease |
| US20130004576A1 (en) * | 2010-03-05 | 2013-01-03 | Alfa Wassermann S.P.A. | Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect |
| US20140012001A1 (en) * | 2010-09-13 | 2014-01-09 | Sequent Scientific Ltd. | Novel polymorphic form of rifaximin and process for its preparation |
-
2015
- 2015-08-04 WO PCT/IN2015/000312 patent/WO2016063289A2/fr active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090312357A1 (en) * | 2006-09-22 | 2009-12-17 | Cipla Limited | Rifaximin |
| US20130004576A1 (en) * | 2010-03-05 | 2013-01-03 | Alfa Wassermann S.P.A. | Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect |
| US20140012001A1 (en) * | 2010-09-13 | 2014-01-09 | Sequent Scientific Ltd. | Novel polymorphic form of rifaximin and process for its preparation |
| US20120245192A1 (en) * | 2010-09-22 | 2012-09-27 | Alfa Wassermann, S.P.A. | Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease |
Non-Patent Citations (1)
| Title |
|---|
| VISCOUNT ET AL.: "Crystal founds of rifaximin and their effect on pharmaceutical properties", CRYST. ENG. COMM., vol. 10, July 2008 (2008-07-01), pages 1077 - 1078, XP009152378 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016063289A2 (fr) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016011222A3 (fr) | Polynucléotides circulaires | |
| EP3139920A4 (fr) | Composés anti-viraux, compositions pharmaceutiques et méthodes d'utilisation de ceux-ci | |
| EP3129028A4 (fr) | Compositions pharmaceutiques | |
| HK1231416A1 (zh) | 西羅莫司及其衍生物的絡合物、其製備方法以及含有其的藥物組合物 | |
| EP3129048A4 (fr) | Anticorps, compositions pharmaceutiques et leurs utilisations | |
| EP3582777A4 (fr) | Composition pharmaceutique d'apixaban | |
| EP3153165A4 (fr) | Dérivés de la rapamycine, leur procédé de préparation, la composition pharmaceutique associée et ses applications | |
| WO2015191945A3 (fr) | Formes solides de sofosbuvir | |
| EP3133071A4 (fr) | Dérivé c-aryl indican et composition pharmaceutique correspondante, procédé de préparation associé et utilisations associées | |
| WO2015104658A3 (fr) | Dispersion solide amorphe de dapagliflozine et procédé pour la préparation de dapagliflozine amorphe | |
| EP3160491A4 (fr) | Compositions pharmaceutiques | |
| PL3223796T3 (pl) | Kompozycje farmaceutyczne, ich wytwarzanie i zastosowania | |
| AU2018302170A1 (en) | Pharmaceutical compositions comprising entrectinib | |
| IL252897A0 (en) | Indanyl compounds, pharmaceutical preparations and their medical uses | |
| EP3429589A4 (fr) | Composition pharmaceutique du nilotinib | |
| EP3402470A4 (fr) | Composition pharmaceutique stable | |
| EP3272362A4 (fr) | Composition pharmaceutique à libération prolongée | |
| EP3229791A4 (fr) | Nouveaux polymorphes d'ivacaftor, procédé de préparation de cette molécule et composition pharmaceutique la contenant | |
| EP3493808A4 (fr) | Compositions pharmaceutiques à base d'ibrutinib | |
| EP3284743A4 (fr) | Composés d'imidazole hétérocycliques, compositions pharmaceutiques les contenant, leur procédé de préparation et utilisation | |
| WO2016063289A3 (fr) | Compositions de comprimé pharmaceutique comprenant de la rifaximine | |
| EP3524250A4 (fr) | Composition pharmaceutique | |
| EP3646867A4 (fr) | Composition pharmaceutique | |
| EP3496714A4 (fr) | Compositions de médicaments. | |
| EP3300474A4 (fr) | Compositions à base de bêta-cryptoxanthine, ses procédés de préparation et ses utilisations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15852354 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15852354 Country of ref document: EP Kind code of ref document: A2 |